Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics develops, manufactures and markets specialty plasma-derived biologics, with news centered on its immune globulin portfolio led by ASCENIV and BIVIGAM. Company updates commonly cover FDA label and post-marketing developments for ASCENIV, primary humoral immunodeficiency indications, product revenue trends, U.S. immune globulin market conditions, and distribution arrangements.
Recurring announcements also address plasma collection and biomanufacturing operations, commercial expansion, cash generation, share repurchases, capital-structure priorities and pipeline updates such as SG-001. ADMA's business updates link manufacturing yield, raw plasma supply, distributor inventory and product demand to its financial results.
ADMA Biologics (Nasdaq: ADMA) reported 1Q 2026 results: $114.5M revenue (flat YoY), ASCENIV revenue $97.5M (+28% YoY), BIVIGAM $15.4M (-54% YoY). The company posted Adjusted Net Income $40.7M (+22% YoY), Adjusted EBITDA $59.7M (+24% YoY), and $58M cash from operations. ADMA updated FY2026 guidance to $530M–$560M revenue, withdrew long‑term guidance, and said market dislocation drove timing and inventory effects while ASCENIV demand remained strong.
ADMA Biologics (Nasdaq: ADMA) announced FDA approval (May 4, 2026) of a supplemental BLA for ASCENIV, expanding the primary humoral immunodeficiency (PI) indication to pediatric patients two years of age and older. The approval reflects the final pediatric assessment required as a post‑marketing commitment and revises ASCENIV prescribing information; the prior pediatric indication started at age 12.
The company said the expanded label enables treatment of younger PI and immune‑compromised patients and follows completion of the clinical program supporting the pediatric assessment.
ADMA Biologics (Nasdaq: ADMA) will report first quarter 2026 financial results on May 6, 2026 after U.S. market close. Management will host a live conference call and audio webcast on May 6 at 4:30 p.m. ET.
Participants must register to receive dial-in numbers and a unique PIN; a replay will be archived under Events & Webcasts on the investor website.
ADMA (Nasdaq: ADMA) issued a detailed rebuttal to a March 24, 2026 short report, calling key allegations about ASCENIV and related‑party dealings "false and misleading." The company says end‑user demand and utilization for ASCENIV are at record highs and provides distributor inventory and pull‑through data.
ADMA cites average distributor inventory as of Jan 5, 2026 (ASCENIV 128 days, BIVIGAM 129 days) and Mar 22, 2026 (ASCENIV 90 days, BIVIGAM 92 days), plus above‑safety‑stock coverage (ASCENIV 84 to 48 days; BIVIGAM 87 to 51 days). ADMA also reports unqualified audit opinions for FY2024 and FY2025 and says its prior auditor resigned in late 2024.
ADMA Biologics (Nasdaq: ADMA) responded on April 6, 2026 to a March 24, 2026 report by Culper Research that disclosed a short position in ADMA.
The company said the report relies on unidentified sources, contains misleading and inaccurate statements, and that ADMA and its board are reviewing the assertions while continuing to report results in accordance with SEC rules and U.S. GAAP.
ADMA (Nasdaq: ADMA) announced a 2026 capital return initiative targeting $200 million, including a $125 million accelerated share repurchase (ASR) with JPMorgan, and plans to complete the ASR within about five months.
The company will initially receive ~6.4 million shares (≈80% of expected ASR shares) based on a $15.57 close on Feb 27, 2026, and retains up to $500 million authorized repurchases.
ADMA (Nasdaq: ADMA) reported record FY2025 results with $510.2M total revenue (+20% YoY), $363M ASCENIV sales (+51% YoY), $160.8M adjusted net income (+35% YoY) and $231.0M adjusted EBITDA (+40% YoY). Management highlighted yield-enhanced production in full commercial operation, a $12M plasma center divestiture pending Q1 2026, ~$88M cash on hand and reiterated 2026–2029 guidance targeting >$1.1B revenue and >$700M adjusted EBITDA in 2029.
Company appointed Terry Kohler as CFO to support capital allocation, working capital execution and continued commercial scaling.
ADMA Biologics (Nasdaq: ADMA) will report its fourth quarter and full year 2025 financial results on February 25, 2026 after market close. Management will host a live conference call and audio webcast at 4:30 p.m. ET to discuss results and company updates.
Participants must register to receive dial-in numbers and a unique PIN; a replay will be archived under Events & Webcasts on the company investor website.
ADMA Biologics (Nasdaq: ADMA) reported preliminary unaudited FY2025 revenue of $510–511 million, year-end cash of ~$88 million, and estimated $40 million of 4Q2025 operating cash flow. The company reiterated FY2025 adjusted EBITDA and adjusted net income guidance and raised FY2026 revenue and adjusted EBITDA targets to $635M and $360M, respectively, with FY2027 revenue and adjusted EBITDA expected at $775M and $455M. ADMA expects 2026 to be its first full year of yield-enhanced production, announced plasma center divestitures for $12M proceeds with long-term supply agreements, and plans an FDA pre-IND submission for SG-001 in 2026. Long-term targets include >$1.1B revenue and >$700M adjusted EBITDA by FY2029.
ADMA Biologics (Nasdaq: ADMA) announced that Adam Grossman, President and CEO, will deliver a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PT.
A live audio webcast will be available under Events & Webcasts in the company investor website and an archived webcast will be posted after the event.